Stay updated on LowDose IL-2 & Pembrolizumab in Melanoma/RCC Clinical Trial
Sign up to get notified when there's something new on the LowDose IL-2 & Pembrolizumab in Melanoma/RCC Clinical Trial page.

Latest updates to the LowDose IL-2 & Pembrolizumab in Melanoma/RCC Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedThe page shows a new revision number (v3.6.4) indicating a recent update to the ClinicalTrials.gov record. No study details or terms appear to be changed in the visible context.SummaryDifference0.1%

- Check21 days agoNo Change Detected
- Check28 days agoNo Change Detected
- Check35 days agoChange DetectedThe page footer now shows Revision: v3.6.3, replacing Revision: v3.6.2. This indicates the page has been updated to a newer revision.SummaryDifference0.1%

- Check42 days agoChange DetectedThe page's revision tag was updated from v3.6.0 to v3.6.2, signaling a backend or template update. This update does not modify the study content or user-facing information on the page.SummaryDifference0.1%

- Check57 days agoChange DetectedAdded new help/navigation sections (How to Read a Study Record, Common Questions, How to Join a Study) and updated the Intervention/Treatment heading; the old Intervention / Treatment label and the previous Revision note (Revision: v3.5.5) were removed, aligning with the new v3.6.0 revision.SummaryDifference0.5%

- Check64 days agoChange DetectedRevision label on the page changes from v3.5.4 to v3.5.5. This reflects a metadata/version update and does not alter the visible content.SummaryDifference0.1%

- Check86 days agoChange DetectedA new revision label (v3.5.4) replaces the previous v3.5.3, indicating a backend or display update without changing the study information presented on the page.SummaryDifference0.1%

Stay in the know with updates to LowDose IL-2 & Pembrolizumab in Melanoma/RCC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the LowDose IL-2 & Pembrolizumab in Melanoma/RCC Clinical Trial page.